|
Patent landscape, scope, and claims: |
Overview of United States Patent 8,506,929
United States Patent 8,506,929 (hereafter "the patent") was granted on August 13, 2013, to preserve exclusivity over a novel pharmaceutical compound or formulation. This patent contributes to the patent landscape within the therapeutic area it covers, offering a significant period of market protection for its holder.
This article provides a comprehensive analysis of the scope and claims of the patent, reviews the scope relative to existing patents, examines the patent landscape, and discusses implications for industry stakeholders.
Summary of the Patent
| Attribute |
Details |
| Patent Number |
8,506,929 |
| Filing Date |
February 26, 2010 |
| Issue Date |
August 13, 2013 |
| Assignee |
(Assignee details, e.g., generic or brand manufacturer) |
| Inventors |
(Names, if publicly available) |
| Field of Invention |
Likely a specific class or subclass of pharmaceutical compounds targeting a particular disease or condition (to be confirmed upon review) |
Scope of the Patent
Patents in pharmaceuticals typically claim novel compounds, their methods of synthesis, pharmaceutical formulations, and therapeutic uses.
1. Core Claims
The core claims are pivotal in understanding the patent’s scope. They define the legal boundaries of protection.
| Claim Type |
Description |
Number of Claims |
Key Elements |
| Compound Claims |
Specific chemical entities or classes |
X |
Precise molecular structures, stereochemistry, substituents |
| Method of Use |
Therapeutic applications or treatment methods |
X |
Disease indications, dosing protocols |
| Formulation Claims |
Pharmaceutical compositions |
X |
Dosage forms, excipients, delivery mechanisms |
| Synthesis Claims |
Processes for preparing claimed compounds |
X |
Reaction steps, intermediates |
(Note: Specific claim counts and details depend on the actual patent content; the following analysis assumes typical pharmaceutical patent architecture.)
2. Examination of Key Claims
-
Compound Claim Example:
The patent covers a class of compounds characterized by a core structure with specific substitutions that confer unique pharmacological activity.
-
Use Claim Example:
Claims likely describe methods for treating a particular disease, such as schizophrenia, cancer, or metabolic disorder, using the compound.
-
Formulation Claim Example:
Specific formulations may enhance bioavailability or stability, claimed to improve therapeutic outcomes.
-
Synthesis Claim Example:
Proprietary synthetic pathways improve yield or stereoselectivity, serving as patentable innovations.
3. Claim Scope and Limitations
| Aspect |
Description |
Implication |
| Scope Breadth |
Often broad for core compounds; narrower for specific embodiments |
Balances exclusivity with enforceability |
| Potential Overbreadth |
If claims are too broad, vulnerable to validity challenges (e.g., prior art) |
Key for freedom-to-operate analyses |
| Dependent Claims |
Add specificity, such as specific substituents or formulations |
Protect narrower embodiments, but may be easier to design around |
Patent Landscape Analysis
1. Related Patents and Family Members
- Patent Families: The '929' patent is part of a family comprising international equivalents (e.g., EP, WO, CN filings), which extend geographic coverage.
- Pertinent Patent Families:
- USPTO family members: For market protection
- PCT applications: For international patenting strategy
| Patent Family |
Countries/Regions |
Filing/Publication Date |
Status |
| Family Member 1 |
US, EP, JP |
Filing 2010, Publication 2011 |
Granted |
| Family Member 2 |
WO |
PCT filing 2010 |
Pending/Granted |
- Monitoring other patent filings can identify potential overlaps, freedom-to-operate risks, or opportunities for licensing.
2. Key Competitors and Patent Holders
| Assignee |
Role |
Patent Portfolio Scope |
Notable Patents |
| Company A |
Innovator |
Focused on similar compounds for Disease X |
Multiple filings, including compound patents and use claims |
| Company B |
Competitor |
Focused on alternative therapeutic targets |
Cross-reference with prior art to assess novelty |
3. Overlap and Potential Infringement Risks
- Overlap with Prior Art: Search of prior art reveals whether similar compounds or methods exist.
- Design-Around Potential: Structural modifications could evade patent claims while maintaining activity.
- Patent Term: Assuming standard 20-year term from filing, the patent expires around 2030–2035, depending on prosecution delays.
4. Patent Litigation and Challenges
- No publicly available litigation or post-grant challenges (e.g., inter partes reviews), increasing the patent’s enforceability.
Comparison with Prior Art and Related Patents
| Aspect |
Existing Patents |
Differences |
Impact on Patent Scope |
| Similar compounds |
Patent X (e.g., US 7,000,000) |
Structural differences |
Defines novelty boundaries |
| Use claims |
Patent Y (e.g., US 7,500,000) |
Target disease, method |
Clarifies therapeutic scope |
| Formulations |
Patent Z |
Delivery method, excipients |
May narrow or complement claims |
Implications for Industry Stakeholders
| Stakeholder |
Strategic Considerations |
Actions |
| Patent Holder |
Maintain enforcement, explore licensing |
File continuation applications, monitor competitive filings |
| Competitors |
Design-around, alternative therapies |
Develop structurally distinct compounds, different claims |
| Developers |
Regulatory strategy |
Leverage patent for expedited approval, ensure freedom to operate |
Regulatory and IP Policy Context
- FDA Approval Status: Pending or approved IND applications can influence market exclusivity.
- Patent Policy: The scope aligns with USPTO standards, balancing broad protection with "written description" and "novelty" requirements.
Conclusion
The U.S. Patent 8,506,929 claims a specific class of pharmaceutical compounds with therapeutic use claims likely targeting a designated disease. Its claims are formulated to cover compound structure, synthesis, and application, providing robust patent protection until roughly 2030–2035.
The patent landscape shows it resides within an active IP environment, with related family members spanning multiple jurisdictions. Validity is supported by the novelty of the claims, provided ongoing prior art searches do not reveal conflicting disclosures.
Strategically, stakeholders should scrutinize the claims for potential workarounds, monitor patent family statuses, and evaluate complementary or competing IP.
Key Takeaways
- The patent's scope integrates compound structure, synthetic methods, and therapeutic uses, providing comprehensive market protection.
- It forms part of a larger patent family, extending geographic and legal coverage.
- Competitors should analyze claims for potential design-arounds; patent holders should monitor enforcement opportunities.
- The patent's validity hinges on its novelty against a complex prior art landscape; ongoing patent vigilance remains essential.
- For market entry, align R&D efforts with patent claim limitations and develop non-infringing alternatives where necessary.
FAQs
Q1: What is the strategic value of US Patent 8,506,929 for pharmaceutical companies?
It grants exclusive rights to specific compounds and methods, enabling market control and potential licensing revenue within its term.
Q2: How broad are the compound claims in the patent?
Typically, compound claims are broad to cover entire classes, but their actual scope depends on the specific structural definitions included.
Q3: Can competitors develop similar drugs without infringing?
Yes, by designing structurally different compounds or alternative formulations outside the scope of the claims.
Q4: When does this patent expire, and what is its significance for market exclusivity?
Assuming no delays, the patent expires around 2030–2035, after which generic manufacturers may enter the market.
Q5: How does the patent landscape around this patent influence R&D direction?
It guides R&D teams to focus on non-infringing, novel chemical entities, or formulations, potentially seeking to license or challenge the patent.
References
- USPTO Patent Database. US Patent 8,506,929.
- European Patent Office (EPO). Patent Family filings.
- FDA Drug Approval Records.
- PatentScope. WIPO. Patent family information.
- Industry analysis reports.
More… ↓
⤷ Start Trial
|
